Zymeworks (ZYME) Profit After Tax (2021 - 2026)
Zymeworks (ZYME) posted Profit After Tax of -$486000.0 for Q1 2026, up 99.41% sequentially from -$82.0 million in Q4 2025, and up 97.8% YoY from -$245702.8 in Q1 2025.
Analysis
Zymeworks (ZYME) Profit After Tax (2021 - 2026) Analysis & Trends
Zymeworks has reported Profit After Tax for 6 years, with the latest figure at -$486000.0 in Q1 2026.
- Quarterly Profit After Tax rose 97.8% year-over-year to -$486000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.1 million (up 29.14% YoY) and the FY2025 annual result came in at -$81.1 million, up 34.06% from the prior year.
- Profit After Tax climbed to -$486000.0 in Q1 2026 per ZYME's latest filing, from -$82.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $309.4 million in Q4 2022 and troughed at -$123.6 million in Q4 2024.
- A 5-year average of -$12.1 million and a median of -$1.5 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 492.78% in 2024, then tumbled 1870.56% in 2025.
- Over 5 years, Profit After Tax stood at $309.4 million in 2022, then plunged by 137.82% to -$117.0 million in 2023, then decreased by 5.65% to -$123.6 million in 2024, then surged by 33.66% to -$82.0 million in 2025, then surged by 99.41% to -$486000.0 in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$486000.0, -$82.0 million, and -$19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | -45.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.15 Mn |
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.38 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.86 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -12.84 Mn |
| Sep 30, 2023 | -29.17 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |